United Health Products Announces Completion of FDA PMA for HemoStyp®

HENDERSON, Nev., Feb. 05, 2018 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC) today announced that, following its January 17 face-to- face meeting with FDA experts and officials, it has  completed and submitted all materials relevant for the premarket approval (PMA) for HemoStyp. The PMA program is designed to confirm the safety of the HemoStyp product for use in internal human procedures. UHP has submitted additional inspection and registration forms to the CtQ Pilot program for final approval and confirmation. The PMA submission is for the approval of Class III indication and internal surgical use of Hemostyp.

The CtQ program is a sub-program of the PMA umbrella specific to facility and production safety. The estimated sales for internal surgical markets for hemostatic products (global hemostatic agents market) in 2017 are expected to be more than $7 billion. HemoStyp belongs to a subset of these markets whose 2017 sales are estimated at approximately $2.8 Billion, and are expected to nearly double to approximately $5.5 Billion by 2022. Overall, the global hemostatic agents market is estimated to grow at 7.1% annually, to reach $8.3 billion by 2022. http://industryarc.com/Report/15189/hemostats-market.html).

About United Health Products

United Health Products (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets. For more on UHP visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact United Health Products: 877-358-3444
IR contact: Philippe Niemetz, PAN Consultants Ltd., 212 344-6464 p.niemetz@panconsultants.com